

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

The Company is pleased to announce that it has initiated pre-clinical trial on application of rExendin-4 on treatment of Type I Diabetes.

Uni-Bio Science Group Limited (the “Company”, and together with its subsidiaries, the “Group”) is pleased to announce that the Phase III clinical trial for Recombinant Exendin-4 (“rExendin-4”) project of the Group is on schedule and over 10 leading hospitals throughout The People’s Republic of China have been chosen.

The rExendin-4 project features a mechanism to stimulate insulin secretion, based on the level of glucose, by increasing intracellular cAMP concentration, i.e., to stimulate insulin secretion when the blood sugar content is high, and not to stimulate insulin secretion when the blood sugar content is low or normal. It is relatively safe, and at the same time able to stimulate the proliferation of pancreas islet β -cells and improve their functionality as well.

Because of the unique mechanism of rExendin-4, our research staff discovered the effectiveness of rExendin-4 on treatment of Type I Diabetes during the animal trials. The Group has co-operated with the Xiangya Hospital, an authoritative unit on treatment of diabetes in China, to initiate a research on the effectiveness of rExendin-4 on Type I Diabetics. Once proved effective, the rExendin-4 will have a new indication with market potential as currently only insulin is used in treatment of Type I Diabetes.

Glossary of terms:

Type I Diabetes is a diabetic with an insulin level lower than 5 μ IU/ml (metric measure) in an empty stomach attributable to under secretion of insulin by destruction or malfunction of pancreas islet β cells. It can take place in people of all ages, particularly in those at ages before 30, and can currently only be treated with insulin.

Type II Diabetes is a diabetic with a blood sugar level of 6.8mmol/L (mM) or above in an empty stomach attributable to pathological changes in insulin receptors (tyrosine receptors) which cause resistance to insulin and affect the proper functioning of insulin.

By order of the board of directors of
Uni-Bio Science Group Limited
Tong Kit Shing
Chairman

Hong Kong, 6 July 2009

As at the date of this announcement, the executive directors of the Company are Mr. Tong Kit Shing (Chairman), Mr. Liu Guoyao and Mr. Cheng Wai Man; the independent non-executive directors of the Company are Mr. Zhou Yaoming, Mr. Lin Jian and Mr. So Yin Wai.

* *For identification purposes only*